Daniel Krappmann
YOU?
Author Swipe
View article: Systematic identification of pan-cancer single-gene expression biomarkers in drug high-throughput screens
Systematic identification of pan-cancer single-gene expression biomarkers in drug high-throughput screens Open
Precision oncology relies on molecular biomarkers to stratify patients into responders and non-responders to a given treatment. Although gene expression profiles have historically been explored for biomarker discovery, fewer studies invest…
View article: A20 intrinsically influences human effector T‐cell survival and function by regulating both NF‐κB and JNK signaling
A20 intrinsically influences human effector T‐cell survival and function by regulating both NF‐κB and JNK signaling Open
A20 is a dual‐function ubiquitin‐editing enzyme that maintains immune homeostasis by restraining inflammation. Although A20 serves a similar negative feedback function for T‐cell receptor (TCR) signaling, the molecular mechanisms utilized …
View article: Activation of the aryl hydrocarbon receptor improves allergen-specific immunotherapy of murine allergic airway inflammation: a novel adjuvant option?
Activation of the aryl hydrocarbon receptor improves allergen-specific immunotherapy of murine allergic airway inflammation: a novel adjuvant option? Open
Background Allergen-specific immunotherapy (AIT) is able to restore immune tolerance to allergens in allergic patients. However, some patients do not or only poorly respond to current treatment protocols. Therefore, there is a need for dee…
View article: MALT1 substrate cleavage: what is it good for?
MALT1 substrate cleavage: what is it good for? Open
CARD-BCL10-MALT1 (CBM) signalosomes connect distal signaling of innate and adaptive immune receptors to proximal signaling pathways and immune activation. Four CARD scaffold proteins (CARD9, 10, 11, 14) can form seeds that nucleate the ass…
View article: The pharmacogenomic assessment of molecular epithelial-mesenchymal transition signatures reveals drug susceptibilities in cancer cell lines
The pharmacogenomic assessment of molecular epithelial-mesenchymal transition signatures reveals drug susceptibilities in cancer cell lines Open
The epithelial-mesenchymal transition (EMT) is characterised by the loss of cell-cell adhesion and cell polarity, which is often exploited by cancer cells to adopt a motile, invasive and metastatic phenotype. Whilst EMT is often linked wit…
View article: SARS-CoV-2 NSP14 MTase activity is critical for inducing canonical NF-κB activation
SARS-CoV-2 NSP14 MTase activity is critical for inducing canonical NF-κB activation Open
Upon SARS-CoV-2 infection, patients with severe forms of COVID-19 often suffer from a dysregulated immune response and hyperinflammation. Aberrant expression of cytokines and chemokines is associated with strong activation of the immunoreg…
View article: Unrestrained cleavage of Roquin-1 by MALT1 induces spontaneous T cell activation and the development of autoimmunity
Unrestrained cleavage of Roquin-1 by MALT1 induces spontaneous T cell activation and the development of autoimmunity Open
Constitutive activation of the MALT1 paracaspase in conventional T cells of Malt1 TBM/TBM (TRAF6 Binding Mutant = TBM) mice causes fatal inflammation and autoimmunity, but the involved targets and underlying molecular mechanisms are unknow…
View article: A gut meta-interactome map reveals modulation of human immunity by microbiome effectors
A gut meta-interactome map reveals modulation of human immunity by microbiome effectors Open
SUMMARY The molecular mechanisms by which the gut microbiome influences human health remain largely unknown. Pseudomonadota is the third most abundant phylum in normal gut microbiomes. Several pathogens in this phylum can inject so-called …
View article: Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas
Oncogene-induced MALT1 protease activity drives posttranscriptional gene expression in malignant lymphomas Open
Constitutive mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) activity drives survival of malignant lymphomas addicted to chronic B-cell receptor signaling, oncogenic CARD11, or the API2-MALT1 (also BIRC3::MALT1) …
View article: Function and targeting of MALT1 paracaspase in cancer
Function and targeting of MALT1 paracaspase in cancer Open
The paracaspase MALT1 has emerged as a key regulator of immune signaling, which also promotes tumor development by both cancer cell-intrinsic and -extrinsic mechanisms. As an integral subunit of the CARD11-BCL10-MALT1 (CBM) signaling compl…
View article: Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer Open
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
View article: Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer Open
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
View article: Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer Open
MALT1 is the effector protein of the CARMA/Bcl10/MALT1 (CBM) signalosome, a multiprotein complex that drives pro-inflammatory signaling pathways downstream of a diverse set of receptors. Although CBM activity is best known for its role in …
View article: Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer Open
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
View article: Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer Open
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
View article: Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer Open
MALT1 is the effector protein of the CARMA/Bcl10/MALT1 (CBM) signalosome, a multiprotein complex that drives pro-inflammatory signaling pathways downstream of a diverse set of receptors. Although CBM activity is best known for its role in …
View article: Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer Open
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
View article: Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer Open
Supplementary Data from MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer
View article: Translational Studies Using the MALT1 Inhibitor ( <i>S</i> )-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in Cancer
Translational Studies Using the MALT1 Inhibitor ( <i>S</i> )-Mepazine to Induce Treg Fragility and Potentiate Immune Checkpoint Therapy in Cancer Open
Introduction Regulatory T cells (Tregs) play a critical role in the maintenance of immune homeostasis but also protect tumors from immune-mediated growth control or rejection and pose a significant barrier to effective immunotherapy. Inhib…
View article: TRAF6 controls T cell homeostasis by maintaining the equilibrium of MALT1 scaffolding and protease functions
TRAF6 controls T cell homeostasis by maintaining the equilibrium of MALT1 scaffolding and protease functions Open
MALT1 is a core component of the CARD11-BCL10-MALT1 (CBM) signalosome, in which it acts as a scaffold and a protease to bridge T cell receptor (TCR) ligation to immune activation. As a scaffold, MALT1 binds to TRAF6, and T cell-specific TR…
View article: Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation
Human TH17 cells engage gasdermin E pores to release IL-1α on NLRP3 inflammasome activation Open
It has been shown that innate immune responses can adopt adaptive properties such as memory. Whether T cells utilize innate immune signaling pathways to diversify their repertoire of effector functions is unknown. Gasdermin E (GSDME) is a …
View article: Human Th17 cells engage gasdermin E pores to release IL-1a upon NLRP3 inflammasome activation
Human Th17 cells engage gasdermin E pores to release IL-1a upon NLRP3 inflammasome activation Open
There is evidence that innate immune responses coopt adaptive properties such as memory. Whether T cells harness innate immune signaling pathways to diversify their repertoire of effector functions remains unknown. Here, we found that huma…
View article: Combining precision oncology and immunotherapy by targeting the MALT1 protease
Combining precision oncology and immunotherapy by targeting the MALT1 protease Open
An innovative strategy for cancer therapy is to combine the inhibition of cancer cell-intrinsic oncogenic signaling with cancer cell-extrinsic immunological activation of the tumor microenvironment (TME). In general, such approaches will f…
View article: Modulation of pre-mRNA structure by hnRNP proteins regulates alternative splicing of <i>MALT1</i>
Modulation of pre-mRNA structure by hnRNP proteins regulates alternative splicing of <i>MALT1</i> Open
Alternative splicing plays key roles for cell type–specific regulation of protein function. It is controlled by cis-regulatory RNA elements that are recognized by RNA binding proteins (RBPs). The MALT1 paracaspase is a key factor of signal…
View article: Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency
Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency Open
This cohort provides the largest analysis for clinical and immunological features of MALT1 deficiency. HSCT should be offered as a curative therapeutic option for all patients at the early stage of life.
View article: Microbial dysbiosis in a mouse model of atopic dermatitis mimics shifts in human microbiome and correlates with the key pro‐inflammatory cytokines IL‐4, IL‐33 and TSLP
Microbial dysbiosis in a mouse model of atopic dermatitis mimics shifts in human microbiome and correlates with the key pro‐inflammatory cytokines IL‐4, IL‐33 and TSLP Open
Background Cutaneous bacterial dysbiosis is a characteristic hallmark of atopic dermatitis (AD), and it decisively influences the severity of the disease. Despite this, frequently used murine models of AD have not been characterized regard…